JNCI· @JNCI_Now · X·· 2 days agoScore90
Body
Interested in context to interpret INTerpath-001 at #ESMO26?
🧵 Ahead of the first phase 3 data for an individualized neoantigen therapy in resected #Melanoma, check these 4 JNCI articles on surrogate endpoints, OS & real-world (neo)adjuvant care
@myESMO
👇👇
#Oncology
551 views · 8 likes · 6 reposts · 1 reply
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgReplies in this thread
- JNCI@JNCI_Now
➡️ https://doi.org/10.1093/jnci/djag183 ➡️ https://doi.org/10.1093/jnci/djag133 ➡️ https://doi.org/10.1093/jnci/djad081 ➡️ https://doi.org/10.1093/jnci/djag230
Source: JNCI · x.com